Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations

被引：0
|
作者：
Cho, B. C. [1 ]
Lu, S. [2 ]
Lee, M. A. [3 ]
Song, Z. [4 ]
Park, J. J. W. [5 ]
Lim, S. M. [6 ]
Li, Z. [2 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [10 ,12 ]
Liu, A. [11 ]
Chen, C. [12 ]
Wang, J. [12 ]
Chen, J. [12 ]
Wang, A. [12 ]
Zhang, J. [10 ,12 ]
Chen, Z. G. [12 ]
Mok, T. S. K. [13 ]
Johnson, M. L. [14 ]
机构：
[1] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[3] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea
[4] Zhejiang Canc Hosp, Phase Clin Trial Ward 1, Hangzhou, Peoples R China
[5] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept, Sydney, NSW, Australia
[6] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, GI Oncol, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Med Oncol, Nanchang, Jiangxi, Peoples R China
[12] D3 Bio, Clin Dev Dept, Shanghai, Peoples R China
[13] Prince Wales Hosp, Li Ka Shing Specialist Clin, Clin Oncol Dept, Hong Kong, Peoples R China
[14] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
615MO
引用
收藏
页码：S493 / S493
页数：1
相关论文
共 50 条
  • [31] RESISTANT KRAS(G12C) INHIBITOR SUBCLONES EXHIBIT HETEROGENEOUS ALTERATIONS
    不详
    CANCER DISCOVERY, 2022, 12 (01) : 13 - 13
  • [32] Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036
    Xu, Jie
    Lim, Ngiap-Kie
    Timmerman, Jacob C.
    Shen, Jeff
    Clagg, Kyle
    Orcel, Ugo
    Bigler, Raphael
    Trachsel, Etienne
    Meier, Roland
    White, Nicholas A.
    Burkhard, Johannes A.
    Sirois, Lauren E.
    Tian, Qingping
    Angelaud, Remy
    Bachmann, Stephan
    Zhang, Haiming
    Gosselin, Francis
    ORGANIC LETTERS, 2023, 25 (19) : 3417 - 3422
  • [33] Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
    Wang, J.
    Zhao, J.
    Zhong, J.
    Li, X.
    Fang, J.
    Yu, Y.
    Li, X.
    Fang, X.
    Chang, J.
    Liu, Z.
    Zhao, Y.
    Song, Q.
    Bai, C.
    Wang-Gillam, A.
    Ding, Y.
    Rao, Z.
    Bi, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S459
  • [34] Development of inhibitors of the activated form of KRAS G12C
    Pollock, R.
    Stewart, M.
    Perl, N.
    Lee, S. J.
    Xue, L.
    Zhou, M.
    Simon, J.
    Luly, K.
    Grigoriu, S.
    Yuzhakov, A.
    Silver, A.
    Lowe, J.
    Mann, A.
    Verdine, G.
    Rigby, A.
    Mulvihill, M.
    May, E.
    Kohlmann, A.
    Townson, S.
    Jin, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E52 - E52
  • [35] KRAS (G12C) mediated mRNA translation program
    Singh, Kamini
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [36] Covalent Guanosine Mimetic Inhibitors of G12C KRAS
    Xiong, Yuan
    Lu, Jia
    Hunter, John
    Li, Lianbo
    Scott, David
    Choi, Hwan Geun
    Lim, Sang Min
    Manandhar, Anuj
    Gondi, Sudershan
    Sim, Taebo
    Westover, Kenneth D.
    Gray, Nathanael S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 61 - 66
  • [37] The emerging target KRAS G12C in genitourinary malignancies
    Grivas, Petros
    Necchi, Andrea
    Bratslavsky, Gennady
    Shapiro, Oleg
    Jacob, Joseph
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Keith
    Williams, Erik
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Hemmerich, Amanda
    Schrock, Alexa Betzig
    Chung, Jon
    McGregor, Kimberly
    Reddy, Prasanth
    Alexander, Brian Michael
    Sokol, Ethan
    Danziger, Natalie
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Two new agents target KRAS G12C
    Diana Romero
    Nature Reviews Clinical Oncology, 2020, 17 (1) : 6 - 6
  • [39] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [40] Two new agents target KRAS G12C
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 6 - 6
12345